ArticleDiagnostic pathology2026
Expression of LDHA, Pan-Kla Level and H3K18la associates with clinical progression of laryngeal squamous cell carcinoma.
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsLaryngeal squamous cell carcinoma (LSCC) represents one of the major subtypes of head and neck squamous cell carcinoma (HNSC), imposing substantial health burdens and necessitates comprehensive clinical interventions. Lactylation, a newly discovered protein post-translational modification (PTM), has recently been recognized as a critical regulatory element in cancer biology and LDHA plays a central role in lactylation modulation. H3K18la, one of the crucial types of histone lactylation, has drawn increasing attention of studies of malignant tumors in recent years. There is no study about the relationship between the expression of LDHA, Pan-Kla level and H3K18la and clinical characteristics and prognosis of LSCC patients.
methodsIt was analyzed that the mRNA expression of LDHA in HNSC in TCGA databases. The expression of LDHA, Pan-Kla level, and H3K18la was detected by immunohistochemistry (IHC) in a large scale of LSCC patients, evaluating their associations with clinicopathologic features and prognosis.
resultsLDHA mRNA was significantly upregulated in HNSC and was associated with poorer prognosis by bioinformatic analysis. Expression of LDHA, Pan-Kla level and H3K18la were higher in LSCC tissues than in non-cancerous laryngeal epithelial tissues. LDHA expression and Pan-Kla level were significantly associated with T stage. H3K18la expression was significantly associated with lymph node metastasis. Kaplan-Meier survival analysis showed that high expression of LDHA, Pan-Kla level and H3K18la was associated with shorter OS in LSCC patients. Multivariate Cox regression analysis identified positive LDHA expression as an independent prognostic indicator for LSCC.
conclusionsLDHA, Pan-Kla level and H3K18la were upregulated in LSCC tissues and were associated with shorter OS. LDHA may serve as an independent prognostic biomarker for patients with LSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.